Premium
Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritis
Author(s) -
Attur Mukundan,
Bingham Clifton O.,
Dave Mandar,
Abramson Steven B.,
Amin Ashok R.
Publication year - 2000
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/(sici)1098-2299(200001)49:1<29::aid-ddr5>3.0.co;2-l
Subject(s) - pharmacogenomics , rheumatoid arthritis , medicine , clinical trial , protocol (science) , arthritis , drug , disease , drug development , bioinformatics , pharmacology , rheumatology , alternative medicine , biology , pathology
Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and 4) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease‐modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. Drug Dev. Res. 49:29–33, 2000. © 2000 Wiley‐Liss, Inc.